drugset
drugset / Trial / NCT04684108

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

NCT04684108 ↗

Phase 1 Active not recruiting 61 enrolled Hangzhou Sumgen Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Timeline

Start
2021-11-04
Primary completion
2024-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SG301 Monoclonal antibody 0.005 mg/kg Intravenous
Subject SG301 Monoclonal antibody 0.05 mg/kg Intravenous
Subject SG301 Monoclonal antibody 0.5 mg/kg Intravenous
Subject SG301 Monoclonal antibody 1 mg/kg Intravenous
Subject SG301 Monoclonal antibody 2 mg/kg Intravenous
Subject SG301 Monoclonal antibody 4 mg/kg Intravenous
Subject SG301 Monoclonal antibody 8 mg/kg Intravenous
Subject SG301 Monoclonal antibody 12 mg/kg Intravenous
Subject SG301 Monoclonal antibody 16 mg/kg Intravenous

Indications

refractory plasma cell neoplasm